Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.13
BAYRY's Cash to Debt is ranked lower than
51% of the 921 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. BAYRY: 0.13 )
BAYRY' s 10-Year Cash to Debt Range
Min: 0.08   Max: No Debt
Current: 0.13

Equity to Asset 0.29
BAYRY's Equity to Asset is ranked higher than
51% of the 842 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. BAYRY: 0.29 )
BAYRY' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.48
Current: 0.29

0.23
0.48
F-Score: 8
Z-Score: 2.35
M-Score: -2.47
WACC vs ROIC
7.11%
11.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.09
BAYRY's Operating margin (%) is ranked higher than
79% of the 870 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.37 vs. BAYRY: 11.09 )
BAYRY' s 10-Year Operating margin (%) Range
Min: -4.21   Max: 12.29
Current: 11.09

-4.21
12.29
Net-margin (%) 8.11
BAYRY's Net-margin (%) is ranked higher than
77% of the 870 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.90 vs. BAYRY: 8.11 )
BAYRY' s 10-Year Net-margin (%) Range
Min: -4.41   Max: 14.56
Current: 8.11

-4.41
14.56
ROE (%) 16.80
BAYRY's ROE (%) is ranked higher than
91% of the 894 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.44 vs. BAYRY: 16.80 )
BAYRY' s 10-Year ROE (%) Range
Min: -9.14   Max: 31.97
Current: 16.8

-9.14
31.97
ROA (%) 5.84
BAYRY's ROA (%) is ranked higher than
81% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.27 vs. BAYRY: 5.84 )
BAYRY' s 10-Year ROA (%) Range
Min: -3.18   Max: 8.79
Current: 5.84

-3.18
8.79
ROC (Joel Greenblatt) (%) 27.39
BAYRY's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 920 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.08 vs. BAYRY: 27.39 )
BAYRY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6.12   Max: 34.99
Current: 27.39

-6.12
34.99
Revenue Growth (3Y)(%) 5.00
BAYRY's Revenue Growth (3Y)(%) is ranked higher than
72% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. BAYRY: 5.00 )
BAYRY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.6   Max: 14
Current: 5

-10.6
14
EPS Growth (3Y)(%) 11.50
BAYRY's EPS Growth (3Y)(%) is ranked higher than
80% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. BAYRY: 11.50 )
BAYRY' s 10-Year EPS Growth (3Y)(%) Range
Min: -19.1   Max: 41.4
Current: 11.5

-19.1
41.4
» BAYRY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BAYRY Guru Trades in Q1 2014

Ken Fisher 270,713 sh (+217.05%)
» More
Q2 2014

BAYRY Guru Trades in Q2 2014

Ken Fisher 2,302,369 sh (+750.48%)
» More
Q3 2014

BAYRY Guru Trades in Q3 2014

Ken Fisher 2,511,364 sh (+9.08%)
» More
Q4 2014

BAYRY Guru Trades in Q4 2014

Ken Fisher 2,493,419 sh (-0.71%)
» More
» Details

Insider Trades

Latest Guru Trades with BAYRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.40
BAYRY's P/E(ttm) is ranked higher than
80% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.40 vs. BAYRY: 33.40 )
BAYRY' s 10-Year P/E(ttm) Range
Min: 8.67   Max: 36.88
Current: 33.4

8.67
36.88
Forward P/E 17.95
BAYRY's Forward P/E is ranked higher than
87% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 67.57 vs. BAYRY: 17.95 )
N/A
PE(NRI) 34.80
BAYRY's PE(NRI) is ranked higher than
82% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.00 vs. BAYRY: 34.80 )
BAYRY' s 10-Year PE(NRI) Range
Min: 14.08   Max: 37.24
Current: 34.8

14.08
37.24
P/B 5.70
BAYRY's P/B is ranked higher than
54% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. BAYRY: 5.70 )
BAYRY' s 10-Year P/B Range
Min: 1.15   Max: 5.89
Current: 5.7

1.15
5.89
P/S 2.72
BAYRY's P/S is ranked higher than
72% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.26 vs. BAYRY: 2.72 )
BAYRY' s 10-Year P/S Range
Min: 0.45   Max: 2.82
Current: 2.72

0.45
2.82
PFCF 33.20
BAYRY's PFCF is ranked higher than
85% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 639.25 vs. BAYRY: 33.20 )
BAYRY' s 10-Year PFCF Range
Min: 7.28   Max: 107
Current: 33.2

7.28
107
POCF 20.45
BAYRY's POCF is ranked higher than
85% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 37.05 vs. BAYRY: 20.45 )
BAYRY' s 10-Year POCF Range
Min: 4.24   Max: 20.45
Current: 20.45

4.24
20.45
EV-to-EBIT 28.98
BAYRY's EV-to-EBIT is ranked higher than
80% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.20 vs. BAYRY: 28.98 )
BAYRY' s 10-Year EV-to-EBIT Range
Min: -17.9   Max: 29
Current: 28.98

-17.9
29
PEG 10.55
BAYRY's PEG is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 10.55 )
BAYRY' s 10-Year PEG Range
Min: 0.6   Max: 6.7
Current: 10.55

0.6
6.7
Shiller P/E 47.60
BAYRY's Shiller P/E is ranked higher than
76% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 111.29 vs. BAYRY: 47.60 )
BAYRY' s 10-Year Shiller P/E Range
Min: 13.49   Max: 50.98
Current: 47.6

13.49
50.98
Current Ratio 1.43
BAYRY's Current Ratio is ranked higher than
58% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. BAYRY: 1.43 )
BAYRY' s 10-Year Current Ratio Range
Min: 1.24   Max: 2.21
Current: 1.43

1.24
2.21
Quick Ratio 0.89
BAYRY's Quick Ratio is ranked higher than
54% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. BAYRY: 0.89 )
BAYRY' s 10-Year Quick Ratio Range
Min: 0.76   Max: 1.48
Current: 0.89

0.76
1.48
Days Inventory 138.11
BAYRY's Days Inventory is ranked higher than
73% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.81 vs. BAYRY: 138.11 )
BAYRY' s 10-Year Days Inventory Range
Min: 126.63   Max: 174.79
Current: 138.11

126.63
174.79
Days Sales Outstanding 78.61
BAYRY's Days Sales Outstanding is ranked higher than
74% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 78.61 vs. BAYRY: 78.61 )
BAYRY' s 10-Year Days Sales Outstanding Range
Min: 64.79   Max: 79.65
Current: 78.61

64.79
79.65

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.91
BAYRY's Dividend Yield is ranked higher than
65% of the 529 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.42 vs. BAYRY: 1.91 )
BAYRY' s 10-Year Dividend Yield Range
Min: 1.46   Max: 3.93
Current: 1.91

1.46
3.93
Dividend Payout 0.37
BAYRY's Dividend Payout is ranked higher than
80% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 0.37 )
BAYRY' s 10-Year Dividend Payout Range
Min: 0.14   Max: 0.89
Current: 0.37

0.14
0.89
Dividend growth (3y) 11.90
BAYRY's Dividend growth (3y) is ranked higher than
83% of the 364 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. BAYRY: 11.90 )
BAYRY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 34.9
Current: 11.9

0
34.9
Yield on cost (5-Year) 2.94
BAYRY's Yield on cost (5-Year) is ranked higher than
78% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. BAYRY: 2.94 )
BAYRY' s 10-Year Yield on cost (5-Year) Range
Min: 2.26   Max: 6.07
Current: 2.94

2.26
6.07

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.30
BAYRY's Price/DCF (Projected) is ranked higher than
84% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.40 vs. BAYRY: 2.30 )
BAYRY' s 10-Year Price/DCF (Projected) Range
Min: 0.8   Max: 1.91
Current: 2.3

0.8
1.91
Price/Median PS Value 2.20
BAYRY's Price/Median PS Value is ranked higher than
56% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. BAYRY: 2.20 )
BAYRY' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 1.76
Current: 2.2

0.42
1.76
Price/Peter Lynch Fair Value 6.50
BAYRY's Price/Peter Lynch Fair Value is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BAYRY: 6.50 )
BAYRY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.75   Max: 5.26
Current: 6.5

0.75
5.26
Earnings Yield (Greenblatt) 3.60
BAYRY's Earnings Yield (Greenblatt) is ranked higher than
76% of the 918 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BAYRY: 3.60 )
BAYRY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 13.9
Current: 3.6

3.5
13.9
Forward Rate of Return (Yacktman) 8.01
BAYRY's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 520 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.39 vs. BAYRY: 8.01 )
BAYRY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 31.6
Current: 8.01

2.2
31.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BAY.Italy, BAY.Spain, BAYN N.Mexico, BAYN.Switzerland, BAYA.Germany, BAYN.Germany,
Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third-largest in the world. HealthCare subgroup is divided into two reporting segments: Pharmaceuticals and Consumer Health. The Pharmaceuticals segment focuses on prescription products, especially for women's healthcare and cardiology and also on specialty therapeutics in the fields of oncology, hematology and ophthalmology. Its Consumer Health segment includes the Consumer Care, Medical Care and Animal Health divisions. It mainly focus on non-prescription medicines, dietary supplements and dermatology products. Crop Science has businesses in seeds, crop protection and non-agricultural pest control. Crop science businesss has two operating segments: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a portfolio of high-value seeds and traits along with chemical and biological pest management solutions, at the same time providing extensive customer service to the agriculture industry. Environmental Science focuses on non-agricultural applications, with a broad portfolio of pest control products and services for areas ranging from the home and garden sector to forestry. The Material Science unit develops, manufactures and markets high-tech polymer materials including polyurethane raw materials, polycarbonates, coating and adhesive raw materials and functional films. This subgroup also manufactures and markets selected inorganic basic chemicals. Material Science is organized into the Polyurethanes, Polycarbonates, and Coatings, Adhesives, Specialties business units, and the Industrial Operations area.
» More Articles for BAYRY

Headlines

Articles On GuruFocus.com
Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
Zoetis Will Benefit from Industry Trends Oct 07 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Ken Fisher's Top Increaes of the Second Quarter Jul 28 2014 
We Are Confident About Baxter's Plan to Create Two Separate Health Care Companies Mar 28 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Ken Fisher for Forbes - 5 Fantastic Stocks for Fretters Jun 26 2013 
Pfizer: A Strong Stock for 2013 Apr 20 2012 
Maxygen Inc. (MAXY): A Magic Formula Stock to Avoid Feb 05 2009 


More From Other Websites
New polymer for transparent sun protection -- Baycusan® C 2000 delivers high SPF and feels pleasant... Mar 27 2015
Regeneron's Eylea Gets FDA Approval for Label Expansion - Analyst Blog Mar 26 2015
Bayer to present new preclinical, early clinical and epidemiological data on advancing portfolio in... Mar 24 2015
Bayer MaterialScience at the in-cosmetics trade show in Barcelona -- The Beauty Enabler -- Relaunch... Mar 23 2015
Bayer Furthers Global Efforts to Lead Fight Against Vector-Borne Diseases Mar 23 2015
Merck Reports Encouraging Data from Cardiovascular Study - Analyst Blog Mar 17 2015
How to trade the German DAX Mar 13 2015
Bayer Seeks Eylea Label Expansion in the EU, Provides View - Analyst Blog Mar 12 2015
Bayer Upbeat, Plans Chemicals IPO by 2016 Mar 11 2015
Kythera's Double Chin Drug Backed by FDA Advisory Committee - Analyst Blog Mar 10 2015
Comings & Goings: Fried, Frank's Co-Head of M&A Moves to Paul Hastings Mar 04 2015
Bayer Q4 Net Income Down Y/Y, Provides 2015 Outlook - Analyst Blog Feb 27 2015
Bayer is 'focusing on life sciences' Feb 26 2015
Bayer R&D budget to increase Feb 26 2015
Financial News Conference -- Address by Dr. Marijn Dekkers -- Chairman of the Board of Management Feb 26 2015
Financial News Conference -- Address by Johannes Dietsch -- Member of the Board of Management Feb 26 2015
Dr. Richard Pott to be Chairman of the Supervisory Board of Bayer MaterialScience Feb 25 2015
Bayer proposes increased dividend for 2014 of EUR 2.25 per share -- Total dividend payout rises 7.1... Feb 25 2015
Avago, Jazz, MercadoLibre Build Bases Before Q4 Reports Feb 23 2015
A 'Great Entry Point' for AbbVie; Pfizer a 'Value Creation Machine' Feb 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK